$9.23
+0.09
(+0.98%)▲
0.92%
Downside
Day's Volatility :1.45%
Upside
0.54%
17.66%
Downside
52 Weeks Volatility :17.66%
Upside
0.0%
Period | Haleon Plc Spon Ads | Index (Russel 2000) |
---|---|---|
3 Months | 8.17% | 0.0% |
6 Months | 11.87% | 0.0% |
1 Year | 3.28% | 0.0% |
3 Years | 23.35% | -20.2% |
Market Capitalization | 41.0B |
Book Value | $1.8 |
Dividend Share | 0.0 |
Dividend Yield | 2.37% |
Earnings Per Share (EPS) | 0.3 |
PE Ratio | 29.9 |
PEG Ratio | 1.69 |
Wall Street Target Price | 9.69 |
Profit Margin | 9.64% |
Operating Margin TTM | 22.44% |
Return On Assets TTM | 4.28% |
Return On Equity TTM | 6.7% |
Revenue TTM | 11.2B |
Revenue Per Share TTM | 2.44 |
Quarterly Revenue Growth YOY | -2.1999999999999997% |
Gross Profit TTM | 6.7B |
EBITDA | 2.6B |
Diluted Eps TTM | 0.3 |
Quarterly Earnings Growth YOY | 0.1 |
EPS Estimate Current Year | 0.39 |
EPS Estimate Next Year | 0.42 |
EPS Estimate Current Quarter | 0.11 |
EPS Estimate Next Quarter | 0.09 |
What analysts predicted
Upside of 4.98%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.1B | - |
Net Income | 858.9M | - |
Net Profit Margin | 7.72% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 13.5B | ↑ 16.65% |
Net Income | 1.6B | ↑ 74.81% |
Net Profit Margin | 11.58% | ↑ 3.86% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 12.9B | ↓ 3.51% |
Net Income | 1.9B | ↑ 21.4% |
Net Profit Margin | 14.56% | ↑ 2.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 10.9B | ↑ 13.76% |
Net Income | 1.1B | ↓ 23.74% |
Net Profit Margin | 9.76% | ↓ 4.8% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 14.4B | ↑ 4.09% |
Net Income | 1.3B | ↓ 1.04% |
Net Profit Margin | 9.28% | ↓ 0.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.8B | ↑ 31.15% |
Net Income | 198.0M | ↓ 42.61% |
Net Profit Margin | 5.22% | ↓ 6.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↓ 21.28% |
Net Income | 481.9M | ↑ 96.46% |
Net Profit Margin | 13.03% | ↑ 7.81% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5B | ↓ 7.84% |
Net Income | 375.9M | ↓ 23.39% |
Net Profit Margin | 10.83% | ↓ 2.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.8B | ↑ 1.67% |
Net Income | 365.0M | ↑ 22.48% |
Net Profit Margin | 13.05% | ↑ 2.22% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5B | ↓ 1.14% |
Net Income | -3.8M | ↓ 100.82% |
Net Profit Margin | -0.11% | ↓ 13.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 5.53% |
Net Income | 534.3M | ↓ 14200.0% |
Net Profit Margin | 14.49% | ↑ 14.6% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 46.8B | - |
Total Liabilities | 10.9B | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 46.5B | ↓ 4.43% |
Total Liabilities | 10.8B | ↓ 4.72% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 46.5B | ↑ 0.94% |
Total Liabilities | 10.8B | ↑ 0.81% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 34.8B | ↑ 1.06% |
Total Liabilities | 18.4B | ↑ 130.31% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 43.4B | ↓ 2.18% |
Total Liabilities | 22.1B | ↓ 5.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.5B | - |
Total Liabilities | 11.5B | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.1B | - |
Total Liabilities | 22.2B | - |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.4B | - |
Total Liabilities | 22.1B | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.0B | - |
Investing Cash Flow | 381.6M | - |
Financing Cash Flow | -1.2B | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↑ 79.01% |
Investing Cash Flow | 1.4B | ↑ 253.95% |
Financing Cash Flow | -3.3B | ↑ 163.46% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 3.62% |
Investing Cash Flow | -44.5M | ↓ 103.2% |
Financing Cash Flow | -1.7B | ↓ 49.28% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.1B | ↑ 52.14% |
Investing Cash Flow | -8.8B | ↑ 26518.18% |
Financing Cash Flow | 6.9B | ↓ 659.14% |
Q1 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 161.3M | - |
Investing Cash Flow | 319.1M | - |
Financing Cash Flow | -493.5M | - |
Q2 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 470.2M | ↑ 190.6% |
Investing Cash Flow | -5.9B | ↓ 1954.64% |
Financing Cash Flow | 5.9B | ↓ 1293.58% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 446.7M | ↑ 0.0% |
Investing Cash Flow | -5.6B | ↑ 0.0% |
Financing Cash Flow | 5.6B | ↑ 0.0% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 824.9M | ↑ 100.0% |
Investing Cash Flow | -10.4B | ↑ 100.0% |
Financing Cash Flow | 10.4B | ↑ 100.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 61.0M | ↓ 91.03% |
Investing Cash Flow | -8.8B | ↑ 2.29% |
Financing Cash Flow | 6.9B | ↓ 19.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 944.9M | ↑ 1127.87% |
Investing Cash Flow | -237.2M | ↓ 97.86% |
Financing Cash Flow | -855.3M | ↓ 109.81% |
Sell
Neutral
Buy
Haleon Plc Spon Ads is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Haleon Plc Spon Ads
Revenue is up for the last 2 quarters, 2.76B → 2.91B (in $), with an average increase of 5.2% per quarter
Netprofit is up for the last 2 quarters, -3.0M → 423.0M (in $), with an average increase of 100.7% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 42.2%
Dodge & Cox
FMR Inc
ClearBridge Advisors, LLC
Fisher Asset Management, LLC
Wellington Management Company LLP
AllianceBernstein L.P.
In the quarter ending March,2024. Haleon Plc Spon Ads has declared dividend of $0.11
Read MoreOrganization | Haleon Plc Spon Ads |
Employees | 25408 |
CEO | Mr. Brian James McNamara |
Industry | Healthcare |
Iqvia Holdings Inc.
$9.23
+0.98%
Viatris Inc.
$9.23
+0.98%
Ge Healthcare Technologies Inc.
$9.23
+0.98%
Tenet Healthcare Corp.
$9.23
+0.98%
Molina Healthcare, Inc.
$9.23
+0.98%
United Therapeutics Corporation
$9.23
+0.98%
Biomarin Pharmaceutical Inc.
$9.23
+0.98%
Edwards Lifesciences Corp.
$9.23
+0.98%
Zimmer Biomet Holdings, Inc.
$9.23
+0.98%